Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
13.93
-1.43 (-9.31%)
At close: Feb 27, 2026, 4:00 PM EST
13.87
-0.06 (-0.43%)
After-hours: Feb 27, 2026, 7:36 PM EST
Wave Life Sciences Revenue
In the year 2025, Wave Life Sciences had annual revenue of $42.73M, down -60.55%. Wave Life Sciences had revenue of $17.25M in the quarter ending December 31, 2025, a decrease of -79.41%.
Revenue (ttm)
$42.73M
Revenue Growth
-60.55%
P/S Ratio
61.38
Revenue / Employee
$148,358
Employees
288
Market Cap
2.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.73M | -65.58M | -60.55% |
| Dec 31, 2024 | 108.30M | -5.00M | -4.42% |
| Dec 31, 2023 | 113.31M | 109.66M | 3,005.10% |
| Dec 31, 2022 | 3.65M | -37.32M | -91.09% |
| Dec 31, 2021 | 40.96M | 20.89M | 104.03% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.00B |
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Adaptive Biotechnologies | 276.98M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
WVE News
- 2 days ago - Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 days ago - Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 9 days ago - Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026 - GlobeNewsWire
- 26 days ago - Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path - Benzinga
- 26 days ago - Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 5 weeks ago - MoneyShow's Best Investment Ideas For 2026: Part 9 - Seeking Alpha
- 6 weeks ago - Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P. - Seeking Alpha